<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2025-604-610</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3836</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Ранний предиктор высокого сердечно-сосудистого риска при системной красной волчанке</article-title><trans-title-group xml:lang="en"><trans-title>Early predictor of high cardiovascular risk in systemic lupus erythematosus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2947-7334</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шалыгина</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shalygina</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шалыгина Мария Владимировна</p><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Maria V. Shalygina</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5793-4689</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попкова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Popkova</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Tatiana V. Popkova</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1784-3699</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Alexander V. Volkov</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1003-2087</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кириллова</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirillova</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Irina G. Kirillova</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2025</year></pub-date><volume>63</volume><issue>6</issue><fpage>604</fpage><lpage>610</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шалыгина М.В., Попкова Т.В., Волков А.В., Кириллова И.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Шалыгина М.В., Попкова Т.В., Волков А.В., Кириллова И.Г.</copyright-holder><copyright-holder xml:lang="en">Shalygina M.V., Popkova T.V., Volkov A.V., Kirillova I.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3836">https://rsp.mediar-press.net/rsp/article/view/3836</self-uri><abstract><p>Системная красная волчанка (СКВ) – хроническое аутоиммунное ревматическое заболевание, которое ассоциируется с высоким риском развития сердечно-сосудистых заболеваний (ССЗ). Современные исследования показывают подверженность пациентов с СКВ раннему развитию атеросклероза, что повышает риск инфарктов и инсультов даже у молодых пациентов. Ранним предиктором ССЗ является артериальная ригидность (АР), оценка которой с помощью таких показателей, как скорость пульсовой волны (СПВ) и индекс аугментации (AIx, augmentation index), позволяет выявить снижение эластичности сосудистых стенок.</p><p>Однако механизмы ее развития у этих больных до конца не изучены, а диагностическое и прогностическое значения АР требуют дальнейшего изучения. Таким образом, исследование АР у пациентов с СКВ представляет значительный научный и клинический интерес.</p><p>Цель исследования – изучить параметры локальной артериальной ригидности у больных системной красной волчанкой и их связь с традиционными факторам риска, шкалой сердечно-сосудистого риска QRISK-3 и клинико-иммунологическими показателями.</p><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включено 114 пациентов с СКВ и 35 лиц контрольной группы, сопоставимых по полу и возрасту. В группе СКВ преобладали женщины (88%), средний возраст составил 37±11 лет. Наиболее частыми клиническим проявлениями СКВ на момент включения в исследование были: поражение суставов – 67 (59%), кожи – 36 (31%), гематологические нарушения – 34 (30%) случая. Позитивный антинуклеарный фактор был выявлен в 100% случаев, повышение уровня антител к двуспиральной ДНК – у 80 (70%), гипокомплементемия у 76 (67%) пациентов. На момент включения в исследование терапию глюкокортикоидами получал 91 (80%) пациент, гидроксихлорохином – 80 (70%), другими цитостатическими препаратами – 39 (34%). Всем участникам выполнялось ультразвуковое исследование (УЗИ) общих сонных артерий с измерением толщины комплекса интима-медиа (КИМ) и исследованием AIx и СПВ в положении лежа. Перед УЗИ все пациенты проходили физикальное и инструментально-лабораторное обследования, оценивалось наличие традиционных факторов риска (ТФР), выполнялся расчет риска развития ССЗ по шкале QRISK-3.</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с СКВ по сравнению с контрольной группой выявлены более высокие значения АР: AIx слева – 1,9 [–0,2; 5,3] против 0,0 [–1,1; 2,1]%; AIx справа – 1,1 [–0,1; 5,1] против 0,1 [–0,6; 2,3]%; СПВ слева – 7,2 [6,1; 8,4] против 6,6 [5,8; 7,6] м/с соответственно (р&lt;0,05 во всех случаях). Выявлена связь между АР и ТФР – возрастом, артериальной гипертензией и дислипидемией, QRISK-3. У больных СКВ, имеющих атеросклеротические бляшки (АТБ), АР сосудов выше по сравнению с больными без АТБ. Выявлена корреляционная связь значений СПВ и AIx с иммунологическими показателями (антитела класса IgG к β2-гликопротеину 1, антитела к цитоплазматическому ядерному антигену SS-A), толщиной КИМ и QRISK-3.</p></sec><sec><title>Выводы</title><p>Выводы. Полученные результаты подчеркивают многофакторный механизм сосудистых изменений при СКВ, включающий ТФР и факторы, связанные с СКВ. Эти данные могут служить основой для более точной стратификации риска и персонализированного подбора терапии у пациентов с СКВ.</p></sec></abstract><trans-abstract xml:lang="en"><p>Systemic lupus erythematosus (SLE) is a chronic autoimmune rheumatic disease associated with a high risk of cardiovascular disease (CVD). Modern studies show that patients with SLE are susceptible to early development of atherosclerosis, which increases the risk of heart attacks and strokes even in young patients. An early predictor of cardiovascular disease (CVD) is arterial stiffness (AS), the assessment of which using such parameters as pulse wave velocity (PWV) and augmentation index (AIx) makes it possible to detect reduced elasticity of the vascular walls. However, the mechanisms of its development in these patients have not been fully studied, and the diagnostic and prognostic values require further study. Thus, the study of arterial stiffness in patients with SLE is of significant scientific and clinical interest.</p><p>The aim – to study the parameters of local arterial stiffness in patients with systemic lupus erythematosus and their relationship with traditional risk factors, the QRISK-3 cardiovascular risk score and clinical and immunological indicators Materials and methods. The study included 114 patients with SLE and 35 ageand sex-matched control participants. Women predominated in the SLE group (88%), with a mean age of 37±11 years. The most common clinical manifestations of SLE at the time of enrollment were joint involvement – in 67 (59%) patients, skin involvement – in 36 (31%), and hematologic disorders – in 34 (30%). A positive ANA was detected in 100% of cases, elevated anti-dsDNA levels in 80 (70%) patients, and hypocomplementemia in 76 (67%). Glucocorticoid therapy was received by 91 (80%) patients, hydroxychloroquine – by 80 (70%) and other cytostatic drugs – by 39 (34%) at the time of inclusion in the study. All participants underwent ultrasound of the common carotid arteries with a study of the AIx and pulse wave velocity (PWV) in the supine position. Before the ultrasound, all patients underwent physical, instrumental and laboratory examinations, the presence of traditional risk factors (TRF) was assessed, and the risk of developing CVD was calculated using the QRISK-3 scale.</p><sec><title>Results</title><p>Results. In patients with SLE, higher AS values were found compared to the control group: AIx on the left – 1.9 [–0.2; 5.3] vs 0.0 [–1.1; 2.1]%; AIx on the right – 1.1 [–0.1; 5.1] vs 0.1 [–0.6; 2.3]%; PWV on the left – 7.2 [6.1; 8.4] vs 6.6 [5.8; 7.6] m/s, respectively (p&lt;0.05 in all cases). A relationship was found between AR and TRF – age, arterial hypertension and dyslipidemia, QRISK-3. In patients with SLE who have atherosclerotic plaques (AP), vascular stiffness is higher compared to patients without AP. A correlation was found between PWV and AIx with immunological parameters (antiβ2-GP1, anti Ro/SS-A), intima-media thickness, and QRISK-3.</p></sec><sec><title>Conclusions</title><p>Conclusions. The obtained results emphasize the multifactorial mechanism of vascular changes in SLE, including TGF, SLE-related factors. These data can serve as a basis for more accurate risk stratification and personalized selection of therapy in patients with SLE.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>системная красная волчанка</kwd><kwd>артериальная ригидность</kwd><kwd>скорость пульсовой волны</kwd><kwd>индекс аугментации</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic lupus erythematosus</kwd><kwd>arterial stiffness</kwd><kwd>pulse wave velocity</kwd><kwd>augmentation index</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-41</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: History and modernity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):397-412 (In Russ.). doi: 10.47360/1995-4484-2022-397-41</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, et al. Autoimmune diseases and cardiovascular risk: A population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022; 400(10354):733-743. doi: 10.1016/S0140-6736(22)01349-6</mixed-citation><mixed-citation xml:lang="en">Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, et al. Autoimmune diseases and cardiovascular risk: A population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022; 400(10354):733-743. doi: 10.1016/S0140-6736(22)01349-6</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dai X, Fan Y, Zhao X. Systemic lupus erythematosus: Updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Ther. 2025;10(1):102. doi: 10.1038/s41392-025-02168-0</mixed-citation><mixed-citation xml:lang="en">Dai X, Fan Y, Zhao X. Systemic lupus erythematosus: Updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Ther. 2025;10(1):102. doi: 10.1038/s41392-025-02168-0</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">McMahon M, Seto R, Skaggs BJ. Cardiovascular disease in systemic lupus erythematosus. Rheumatol Immunol Res. 2021;2(3):157-172. doi: 10.2478/rir-2021-0022</mixed-citation><mixed-citation xml:lang="en">McMahon M, Seto R, Skaggs BJ. Cardiovascular disease in systemic lupus erythematosus. Rheumatol Immunol Res. 2021;2(3):157-172. doi: 10.2478/rir-2021-0022</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Васюк ЮА, Иванова СВ, Школьник ЕЛ, Котовская ЮВ, Милягин ВА, Олейников ВЭ, и др. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваскулярная терапия и профилактика. 2016;15(2):4-19. doi: 10.15829/1728-8800-2016-2-4-19</mixed-citation><mixed-citation xml:lang="en">Vasyuk YuA, Ivanova SV, Shkolnik EL, Kotovskaya YuV, Milyagin VA, Oleynikov VE, et al. Consensus of Russian experts on the evaluation of arterial stiffness in clinical practice. Cardiovascular Therapy and Prevention. 2016;15(2):4-19 (In Russ.). doi: 10.15829/1728-8800-2016-2-4-19</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Triantafyllias K, Thiele LE, Cavagna L, Baraliakos X, Bertsias G, Schwarting A. Arterial stiffness as a surrogate marker of cardiovascular disease and atherosclerosis in patients with arthritides and connective tissue diseases: A literature review. Diagnostics (Basel). 2023;13(11):1870. doi: 10.3390/diagnostics13111870</mixed-citation><mixed-citation xml:lang="en">Triantafyllias K, Thiele LE, Cavagna L, Baraliakos X, Bertsias G, Schwarting A. Arterial stiffness as a surrogate marker of cardiovascular disease and atherosclerosis in patients with arthritides and connective tissue diseases: A literature review. Diagnostics (Basel). 2023;13(11):1870. doi: 10.3390/diagnostics13111870</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Berger M, Fesler P, Roubille C. Arterial stiffness, the hidden face of cardiovascular risk in autoimmune and chronic inflammatory rheumatic diseases. Autoimmun Rev. 2021;20(9):102891. doi: 10.1016/j.autrev.2021.102891</mixed-citation><mixed-citation xml:lang="en">Berger M, Fesler P, Roubille C. Arterial stiffness, the hidden face of cardiovascular risk in autoimmune and chronic inflammatory rheumatic diseases. Autoimmun Rev. 2021;20(9):102891. doi: 10.1016/j.autrev.2021.102891</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, et al.; American Heart Association Council on Hypertension. Recommendations for improving and standardizing vascular research on arterial stiffness: A scientific statement from the American Heart Association. Hypertension. 2015;66(3):698-722. doi: 10.1161/HYP.0000000000000033</mixed-citation><mixed-citation xml:lang="en">Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, et al.; American Heart Association Council on Hypertension. Recommendations for improving and standardizing vascular research on arterial stiffness: A scientific statement from the American Heart Association. Hypertension. 2015;66(3):698-722. doi: 10.1161/HYP.0000000000000033</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Arida A, Protogerou AD, Kitas GD, Sfikakis PP. Systemic inflammatory response and atherosclerosis: The paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018;19(7):1890. doi: 10.3390/ijms19071890</mixed-citation><mixed-citation xml:lang="en">Arida A, Protogerou AD, Kitas GD, Sfikakis PP. Systemic inflammatory response and atherosclerosis: The paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018;19(7):1890. doi: 10.3390/ijms19071890</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473</mixed-citation><mixed-citation xml:lang="en">Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Асеева ЕА, Соловьев СК, Насонов ЕЛ. Современные методы оценки активности системной красной волчанки. Научнопрактическая ревматология. 2013;51(2):186-200. doi: 10.14412/1995-4484-2013-648</mixed-citation><mixed-citation xml:lang="en">Aseeva EA, Solovyev SK, Nasonov EL. Current methods for evaluating the activity of systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2013;51(2): 186-200 (In Russ.). doi: 10.14412/1995-4484-2013-648</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Соловьева ЕС, Асеева ЕА, Лисицына ТА, Попкова ТВ, Соловьев СК, Насонов ЕЛ. Необратимые органные повреждения у больных системной красной волчанкой. Индекс повреждения SLICC. Современная ревматология. 2016;10(1):56-62. doi: 10.14412/1996-7012-2016-1-56-62</mixed-citation><mixed-citation xml:lang="en">Solovyeva ES, Aseeva EA, Lisitsyna TA, Popkova TV, Solovyev SK, Nasonov EL. Irreversible organ damages in patients with systemic lupus erythematosus. SLICC damage index. Modern Rheumatology Journal. 2016;10(1):56-62 (In Russ.). doi: 10.14412/1996-7012-2016-1-56-62</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ. 2017;357:j2099. doi: 10.1136/bmj.j2099</mixed-citation><mixed-citation xml:lang="en">Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ. 2017;357:j2099. doi: 10.1136/bmj.j2099</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ежов МВ, Кухарчук ВВ, Сергиенко ИВ, Алиева АС, Анциферов МБ, Аншелес АА, и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. [Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA, et al. Disorders of lipid metabolism. Clinical guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471 (In Russ.)]. doi: 10.15829/15604071-2023-5471</mixed-citation><mixed-citation xml:lang="en">Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA, et al. Disorders of lipid metabolism. Clinical guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471 (In Russ.). doi: 10.15829/15604071-2023-5471</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Stortz M, Triantafyllias K, Schwarting A, Weinmann-Menke J. Vascular stiffness: Influencing factors on carotid-femoral pulse wave velocity in systemic lupus erythematosus. Clin Exp Rheumatol. 2020;38(1):74-81.</mixed-citation><mixed-citation xml:lang="en">Stortz M, Triantafyllias K, Schwarting A, Weinmann-Menke J. Vascular stiffness: Influencing factors on carotid-femoral pulse wave velocity in systemic lupus erythematosus. Clin Exp Rheumatol. 2020;38(1):74-81.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Söderström M, Grönlund C, Liv P, Nyman E, Näslund U, Wester P. Aortic arterial stiffness associates with carotid intima-media thickness and carotid plaques in younger middle-aged healthy people. Blood Press. 2024;33(1):2405161. doi: 10.1080/08037051.2024.2405161</mixed-citation><mixed-citation xml:lang="en">Söderström M, Grönlund C, Liv P, Nyman E, Näslund U, Wester P. Aortic arterial stiffness associates with carotid intima-media thickness and carotid plaques in younger middle-aged healthy people. Blood Press. 2024;33(1):2405161. doi: 10.1080/08037051.2024.2405161</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Čypienė A, Dadonienė J, Miltinienė D, Rinkūnien E, Rugienė R, Stropuvienė S, et al. The fact not to ignore: Mean blood pressure is the main predictor of increased arterial stiffness in patients with systemic rheumatic diseases. Adv Med Sci. 2017;62(2):223-229. doi: 10.1016/j.advms.2017.01.005</mixed-citation><mixed-citation xml:lang="en">Čypienė A, Dadonienė J, Miltinienė D, Rinkūnien E, Rugienė R, Stropuvienė S, et al. The fact not to ignore: Mean blood pressure is the main predictor of increased arterial stiffness in patients with systemic rheumatic diseases. Adv Med Sci. 2017;62(2):223-229. doi: 10.1016/j.advms.2017.01.005</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Valero-Gonzalez S, Castejon R, Jimenez-Ortiz C, Rosado S, Tutor-Ureta P, Vargas JA, et al. Increased arterial stiffness is independently associated with metabolic syndrome and damage index in systemic lupus erythematosus patients. Scand J Rheumatol. 2014;43(1):54-58. doi: 10.3109/03009742.2013.803150</mixed-citation><mixed-citation xml:lang="en">Valero-Gonzalez S, Castejon R, Jimenez-Ortiz C, Rosado S, Tutor-Ureta P, Vargas JA, et al. Increased arterial stiffness is independently associated with metabolic syndrome and damage index in systemic lupus erythematosus patients. Scand J Rheumatol. 2014;43(1):54-58. doi: 10.3109/03009742.2013.803150</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">McDonnell T, Wincup C, Buchholz I, Pericleous C, Giles I, Ripoll V, et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev. 2020;39:100610. doi: 10.1016/j.blre.2019.100610</mixed-citation><mixed-citation xml:lang="en">McDonnell T, Wincup C, Buchholz I, Pericleous C, Giles I, Ripoll V, et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev. 2020;39:100610. doi: 10.1016/j.blre.2019.100610</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Parra S, Lopez-Dupla M, Ibarretxe D, de Las Heras M, Amigó N, Català A, et al. Patients with systemic lupus erythematosus show an increased arterial stiffness that is predicted by IgM anti-β2glycoprotein I and small dense high-density lipoprotein particles. Arthritis Care Res (Hoboken). 2019;71(1):116-125. doi: 10.1002/acr.23594</mixed-citation><mixed-citation xml:lang="en">Parra S, Lopez-Dupla M, Ibarretxe D, de Las Heras M, Amigó N, Català A, et al. Patients with systemic lupus erythematosus show an increased arterial stiffness that is predicted by IgM anti-β2glycoprotein I and small dense high-density lipoprotein particles. Arthritis Care Res (Hoboken). 2019;71(1):116-125. doi: 10.1002/acr.23594</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mangoni AA, Sotgia S, Zinellu A, Carru C, Pintus G, Damiani G, et al. Methotrexate and cardiovascular prevention: An appraisal of the current evidence. Ther Adv Cardiovasc Dis. 2023;17:17539447231215213. doi: 10.1177/17539447231215213</mixed-citation><mixed-citation xml:lang="en">Mangoni AA, Sotgia S, Zinellu A, Carru C, Pintus G, Damiani G, et al. Methotrexate and cardiovascular prevention: An appraisal of the current evidence. Ther Adv Cardiovasc Dis. 2023;17:17539447231215213. doi: 10.1177/17539447231215213</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Verhoeven F, Prati C, Chouk M, Demougeot C, Wendling D. Methotrexate and cardiovascular risk in rheumatic diseases: A comprehensive review. Expert Rev Clin Pharmacol. 2021;14(9):1105-1112. doi: 10.1080/17512433.2021.1932461</mixed-citation><mixed-citation xml:lang="en">Verhoeven F, Prati C, Chouk M, Demougeot C, Wendling D. Methotrexate and cardiovascular risk in rheumatic diseases: A comprehensive review. Expert Rev Clin Pharmacol. 2021;14(9):1105-1112. doi: 10.1080/17512433.2021.1932461</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Xie F, Chen L, Yun H, Levitan EB, Curtis JR. Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs. J Rheumatol. 2021;48(6):804-812. doi: 10.3899/jrheum.191326</mixed-citation><mixed-citation xml:lang="en">Xie F, Chen L, Yun H, Levitan EB, Curtis JR. Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs. J Rheumatol. 2021;48(6):804-812. doi: 10.3899/jrheum.191326</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
